Abstract A090: Preclinical efficacy of BDTX-4933, a brain-penetrant, orthosteric RAF inhibitor, targeting oncogenic RAF conformation shared by groups of BRAF and upstream driver mutations

• Published in: Molecular cancer therapeutics Vol. 22; no. 12_Supplement; p. A090
• Main Authors: Han, Yoon-Chi, Ng, Pui Yee, Ogawa, Luisa Shin, Yang, Shao Ning, Chen, Miao, Romashko, Darlene, Lin, Tai-An, Buck, Elizabeth
• Format: Journal Article
• Language: English
• Published: 01.12.2023

Abstract Alterations in the RAS-MAPK pathway, such as mutations in NF1, RAS, and BRAF, often lead to oncogenic signaling and result in aberrant cell proliferation and tumor growth. Oncogenic BRAF mutations may be activated as either monomers or dimers, while oncogenic RAS mutations or loss-of-functi...